

Inhaled Aztreonam Lysine for Chronic Airway *Pseudomonas aeruginosa* in


Cystic Fibrosis

Karen S McCoy, Alexandra L Quittner, Christopher M Oermann,


Ronald L Gibson, George Z Retsch-Bogart, A Bruce Montgomery

ONLINE DATA SUPPLEMENT

Supplemental Online Figure E1. Observed Mean Percentage Change in FEV₁ (L). Patients were randomly assigned to treatment groups at Day -28, and all three treatment groups received TIS during the open-label, TIS run-in period. AZLI/placebo treatment began on Day 0. For this analysis, the last observation carried forward convention was not used.



Supplemental Online Figure E2. Day 28 Percentage Change from Baseline FEV₁ vs. Day 28 Change from Baseline CFQ-R-Respiratory Scores for Individual Patients in the AZLI-BID, AZLI-TID, and Placebo Treatment Groups



Pearson correlation coefficient for AZLI BID is 0.33, for AZLI TID is 0.24, and for Placebo is 0.33